Potential Role for CAR T-Cell Therapy in MM at Early Relapse
Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.
EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma
EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM
EP: 3.Advances in the Treatment of High-Risk MM
EP: 4.Role of Transplant and MRD in Newly Diagnosed MM
EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM
EP: 6.Treatment of Multiple Myeloma at Early Relapse
EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse
EP: 8.Updates on BCMA-Targeting Bispecifics in MM
EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma
EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma
EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma
EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma
EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma
This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.
The discussion focuses on recent phase 3 trial data for B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapies in earlier lines of therapy for multiple myeloma (MM) and how this may shape incorporation into clinical practice. The CARTITUDE-4 and KarMMa-3 trials evaluated ciltacabtagene autoleucel and idecabtagene vicleucel, respectively, in heavily pretreated patients who were mostly lenalidomide-refractory, demonstrating significantly improved progression-free survival over standard therapies.
While promising, there are reservations around widely adopting CAR T-cell therapy at first relapse until long-term benefit is proven. However, for high-risk patients relapsing within 1 to 2 years of diagnosis who rapidly exhaust available therapies, earlier CAR T-cell therapy may be preferred over trying additional conventional salvage regimens with marginal benefit. Still, triaging will be necessary given manufacturing constraints on cell therapy availability. Thoughtful patient selection that balances risk, available therapy options, and logistics is advocated.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
